Recently, Rizzo et al.[23] reported that MAGE reduction is associated with reduction of oxidative stress and markers of systemic inflammation by treatment of dipeptidyl peptidase-IV inhibitor in type 2 diabetic patients. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.